
Iruplinalkib
CAS No. 1854943-32-0
Iruplinalkib( —— )
Catalog No. M35759 CAS No. 1854943-32-0
Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 117 | Get Quote |
![]() ![]() |
10MG | 188 | Get Quote |
![]() ![]() |
25MG | 419 | Get Quote |
![]() ![]() |
50MG | 634 | Get Quote |
![]() ![]() |
100MG | 888 | Get Quote |
![]() ![]() |
500MG | 1782 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameIruplinalkib
-
NoteResearch use only, not for human use.
-
Brief DescriptionIruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
-
DescriptionIruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK | ROS Kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1854943-32-0
-
Formula Weight569.08
-
Molecular FormulaC29H38ClN6O2P
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 10 mg/mL (17.57 mM; Ultrasonic (<60°C)
-
SMILESO=P(C=1C=CC=CC1NC2=NC(=NC=C2Cl)NC3=CC=C(C=C3OC)N4CCC5(CC4)CCN(C)CC5)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shi Y, et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7(1):25. ?
molnova catalog



related products
-
INCB-000928
Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
-
CEP-28122
A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.
-
AZD3463
AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.